Abstract
Introduction
Natalizumab is a monoclonal antibody used to treat relapsing multiple sclerosis (MS). Its mode of action is to produce a blockage of an integrin adhesion molecule, thereby preventing white blood cells from crossing the bloodbrain barrier and restricting the inflammatory response. It is administered intravenously once every 4 weeks (dose: 300 mg) in adult patients with relapsing MS in whom it is known to substantially decrease disease activity and prevent disease progression. However, its therapeutic efficacy has to be weighed against a serious associated side effect: the likelihood of developing progressive multifocal leukoencephalopathy (PML). PML is an opportunistic infection of the brain parenchyma caused by the JC virus and is known to show high morbidity and mortality rates (1-7).
Case Report
An adult male patient (aged 40 years) was being treated at our hospital (1) for relapsing MS since 1998. He had been on natalizumab therapy for 6 years until being diagnosed with PML in April 2014, after which natalizumab was discontinued. Magnetic resonance imaging (MRI) of the brain in April 2014 showed a large, poorly marginated, T2 hyperintense lesion involving the left middle cerebellar peduncle (MCP) and left cerebellar hemisphere (Figure 1 ). The patient was subsequently treated over one week with intravenous methylprednisolone. A follow-up MRI after 6 weeks showed a decrease in the size and a decrease in the previously noted contrast enhancement of the PML-IRIS lesion. The patient showed parallel clinical improvement. He is presently on oral maintenance steroid therapy.
Discussion
After the first 2-3 years of treatment with natalizumab, the PML incidence increases with increased duration of drug exposure. Patients develop symptoms approximately 17-25 months after treatment (3, 4) . The approximate risk of developing PML in MS patients treated with natalizumab is about 3-4/1000 (4). Cumulative increased exposure to natalizumab increases the risk of developing PML. The risk is significantly higher in patients who have previously received immunosuppressive treatments or in combination with natalizumab. In our patient, the delayed appearance of PML after 6 years may be explained by the fact that he was not treated with other immunosuppressants. Reports in the literature also mention a low viral load and high anti-JCV antibody titre as possible causes for decreased susceptibility to PML (5, 6) .
The presenting symptoms of PML in MS patients include progressive clinical deterioration, changes in cognition and personality, aphasia, hemiparesis, seizures and visual disturbances. The pathological hallmark of PML is a progressive demyelination of oligodendrocytes without a significant inflammatory response. Its clinical diagnosis is aided by a MRI evaluation and the detection of JCV DNA on CSF analysis. Early diagnosis of PML is crucial because a delay in the diagnosis has a negative impact on the overall prognosis (1) (2) (3) (4) (5) (6) (7) (8) .
An awareness of the MRI features of PML is of paramount importance. The common sites for the development of PML lesions are the supratentorial subcortical white matter, with occasional involvement of the deep grey matter. The brainstem and cerebellum are often involved; however, spinal cord involvement is rare. The MRI diagnosis of PML in patients with MS and the decision of whether a new lesion is MS or PML is challenging, especially as it affects therapy. Characteristic MRI features of PML in MS include large, diffuse and asymmetric (> 3 cm), unifocal or multifocal, subcortical white matter lesions (affecting "U" fibres) that are hyperintense on T2W and FLAIR sequences and hypointense on T1W sequences. The lesions typically show a well-marginated border towards the grey matter and a poorly-marginated border towards the white matter. On the other hand, MS lesions are smaller, typically ovoid or flameshaped, commonly seen in the periventricular white matter, often seen in the spinal cord, may show restricted diffusion, have mild mass effect and have a ring-like enhancement in the acute/ active phase. PML lesions typically do not show mass effect. PML is characterised histologically by paucity of inflammation and hence, contrast-enhancement is uncommon (4) (5) (6) (7) (8) (9) (10) (11) .
PML linked to natalizumab treatment is associated with 20% mortality rates with survivors sustaining moderate to severe disabilities. It is treated by the immediate discontinuation of the drug and often, plasmapheresis is performed to rapidly remove the drug from the circulation. Adjuvant immunomodulatory therapy with mefloquine and mirtazapine has been reported to show favourable responses (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) .
Unfortunately, as in our patient, the sudden removal of natalizumab or the use of plasmapheresis may lead to the development of IRIS, which is defined as a paradoxical clinical and radiographic worsening after a period of stability. PML-IRIS typically presents with a worsening of earlier PML symptoms; this occurs a few days to weeks after natalizumab discontinuation or the start of plasmapheresis. Immune reconstitution is characterised by intense perivascular CD4 lymphocytic infiltration and inflammatory brain damage. IRIS is associated with mortality rates of 20-30%. Important MRI features of PML-IRIS include the development of new inflammatory changes with an increase in PML lesion size. There may be an interval appearance of contrast-enhancement, oedema and mass effect. PML-IRIS has also been described in HIV-positive patients being treated by highly active antiretroviral therapy, in which case, infection and lymphoma are likely imaging differentials for PML-IRIS lesions. However, a correlation between the clinical scenario of MS post-natalizumab therapy and the typical MRI findings of PML lesions showing enhancements clinches the IRIS diagnosis. PML-IRIS can lead to substantial long-term sequelae with more extensive necrotic tissue damage than just the JCV infection with severe residual parenchymal and cortical atrophy (4) (5) (6) (7) (8) (9) (10) (11) .
Corticosteroid therapy in high doses, which is usually intravenous methylprednisolone (1 g per day) for 5 days, is the recommended treatment for PML-IRIS. This is followed by oral steroids with tapered doses. Prednisolone in a dose of 0.75 mg/kg has been suggested by some authors as an acceptable taper dose for some forms of IRIS (12) . IRIS can persist for several months and hence, long-term steroid therapy may be necessary along with close clinical and MRI monitoring (2, 3) . Favourable responses to treatment are associated with a gradual regression of the acute inflammatory features on MRI (8) .
In conclusion, diagnosing natalizumabassociated PML-IRIS is of paramount importance. It requires regular clinical followup and vigilance, reliable JCV PCR testing and well-defined MRI criteria for the recognition of PML-IRIS. Optimised treatment strategies of IRIS reactions and the development of robust predictive markers for patients at risk for PML must be sought. Clinicians and radiologists must work in close collaboration to avoid a misdiagnosis of these potentially lethal conditions.
